SCHEMBL6897865

SCHEMBL6897865

O=C(NC1(C(=O)O)CC1)N(CCO)CCC1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.36
KDM5A P29375 3/20 0.35
PHF8 Q9UPP1 3/20 0.35
KDM2A Q9Y2K7 3/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM4A O75164 1/20 0.35
CNR1 P21554 3/20 0.34
CNR2 P34972 3/20 0.34
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
LPAR1 Q92633 4/20 0.32
HPGD P15428 1/20 0.32
GRM2 Q14416 1/20 0.32
ALDH1A1 P00352 3/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
EPHX1 P07099 1/20 0.31
MAPT P10636 2/20 0.30
NPSR1 Q6W5P4 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6895192 0.96 CNR2 (0.38) CASRKDM5APHF8KDM2AKDM4C
SCHEMBL6898778 0.80 ALDH1A1 (0.33) CNR1CTSLCTSBALDH1A1SIGMAR1
SCHEMBL6898356 0.79 CASR (0.39) CASRCTSLCTSBLPAR1ALDH1A1
SCHEMBL6899147 0.77 CTSB (0.34) CTSLCTSBALDH1A1MAPTSIGMAR1
SCHEMBL6890662 0.76 CTSL (0.40) CASRCTSLCTSBLPAR1ALDH1A1
SCHEMBL4667724 0.76 KDM5A (0.40) CASRKDM5APHF8KDM2AKDM4C
SCHEMBL6895667 0.74 CXCR2 (0.37) CASRKDM5APHF8KDM2AKDM4C
SCHEMBL27560018 0.74 CASR (0.32) CASR
SCHEMBL6894998 0.73 LTA4H (0.42) CASRKDM5APHF8KDM2AKDM4C
SCHEMBL6737845 0.73 SIGMAR1 (0.46) CASRKDM5APHF8KDM2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH CASR 2206/4885KDM5A 3320/4885PHF8 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.